h-prune Is an Independent Prognostic Marker for Survival in Esophageal Squamous Cell Carcinoma
h-prune Is an Independent Prognostic Marker for Survival in Esophageal Squamous Cell Carcinoma
复制标题
DOI：
10.1245/s10434-007-9585-3
复制
发表时间：
2009-05-01
影响因子：
3.7
通讯作者：
Yasui, Wataru
中科院分区：
文献类型：
--
作者：
Noguchi, Tsuyoshi;Oue, Naohide;Yasui, Wataru
果蝇Prune(Prune，编码h-prune)蛋白的人类同源物与糖原合成酶激酶3相互作用，促进细胞运动。本研究采用免疫组织化学方法检测205例手术切除的食管鳞癌标本中h-prune的表达，以探讨h-prune表达对食管鳞癌患者生存的影响。H修剪阳性鳞癌的T分期(P<；0.0001)、N分期(P<；0.0001)和肿瘤分期(P<；0.0001)均高于h修剪阴性病例。在116例II期和III期ESCC病例中，h修剪阳性的病例中，ESCC的复发最多见。在肺部复发的患者中，h-prune阳性的可能性比h-prune阴性的可能性更大。单因素分析显示，T分期(P<；0.0001)、N分期(P<；0.0001)、肿瘤分期(P<；0.0001)和h-prune染色(P<；0.0001)是影响预后的重要因素。多因素分析显示，N分期(P=0.0182)和h-prune染色(P<；0.0001)是食管癌患者生存的独立预测因素，提示h-prune免疫组织化学染色有助于确定食管癌复发风险高或预后差的患者。
The human homologue of Drosophila prune (PRUNE, which encodes h-prune) protein interacts with glycogen synthase kinase 3 and promotes cell motility. The aim of our study was to investigate the impact of immunohistochemically detected h-prune expression on the survival of patients with esophageal squamous cell carcinoma (ESCC).Immunohistochemical staining of h-prune was performed for 205 surgically resected specimens of ESCC.In total, 43 (21%) of 205 ESCC cases were positive for h-prune. h-prune-positive ESCC cases showed a more-advanced T stage (P < 0.0001), N stage (P < 0.0001), and tumor stage (P < 0.0001) than h-prune-negative ESCC cases. In the group of 116 stage II and III ESCC cases, recurrence of ESCC was frequently found in h-prune-positive cases. In patients with lung recurrence, the tumors were more likely to be h-prune positive than h-prune negative. Univariate analysis revealed that T stage (P < 0.0001), N stage (P < 0.0001), tumor stage (P < 0.0001), and h-prune staining (P < 0.0001) were significant prognostic factors for survival. Multivariate analysis indicated that N stage (P = 0.0182) and h-prune staining (P < 0.0001) were independent predictors for survival.These results indicate that immunostaining of h-prune is useful to identify patients at high risk for recurrence or poor prognosis associated with ESCC.